You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
(R)-(+)-Methanandamide (in Tocrisolve™ 100)
Stable anandamide analog that is a selective agonist for the CB1 receptor (Ki values are 20 and 815 nM for CB1 and CB2 receptors respectively), in water-soluble emulsion (for details see TocrisolveTM 100). Displays agonist activity at vanilloid receptors.
(R)-(+)-Methanandamide, pure oil dissolved in ethanol and Tocrisolve Control also available.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Abadji et al (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J.Med.Chem. 37 1889 PMID: 8021930
Carriero et al (1998) A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl.) 137 147 PMID: 9630001
Khanolkar et al (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J.Med.Chem. 39 4515 PMID: 8893848
Zygmunt et al (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 452 PMID: 10440374
If you know of a relevant reference for (R)-(+)-Methanandamide (in Tocrisolve™ 100), please let us know.
View Related Products by Product Action
Keywords: (R)-(+)-Methanandamide (in TocrisolveTM 100), (R)-(+)-Methanandamide (in TocrisolveTM 100) supplier, Potent, selective, CB1, agonists, water-soluble, emulsion, cannabinoids, Receptors, cb1r, TocrisolveTM100, 1782, Tocris Bioscience
3 Citations for (R)-(+)-Methanandamide (in Tocrisolve™ 100)
Citations are publications that use Tocris products. Selected citations for (R)-(+)-Methanandamide (in Tocrisolve™ 100) include:
Grace et al (2014) Identification of a pharmacological target for genioglossus reactivation throughout sleep. Int J Neuropsychopharmacol 37 41 PMID: 24470694
Sánchez-Blázquez et al (2014) The calcium-sensitive σ-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. J Neuroimmune Pharmacol 17 1943 PMID: 24485144
Garzón et al (2009) Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with mor. Mol Pain 5 11 PMID: 19284549
Do you know of a great paper that uses (R)-(+)-Methanandamide (in Tocrisolve™ 100) from Tocris? Please let us know.
Reviews for (R)-(+)-Methanandamide (in Tocrisolve™ 100)
There are currently no reviews for this product. Be the first to review (R)-(+)-Methanandamide (in Tocrisolve™ 100) and earn rewards!
Have you used (R)-(+)-Methanandamide (in Tocrisolve™ 100)?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.